Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients.
Breast
/ cytology
Breast Neoplasms
/ blood
CD3 Complex
/ metabolism
CD8 Antigens
/ metabolism
Chemokine CCL7
/ blood
Cytokines
/ blood
Disease Progression
Female
Humans
Immunohistochemistry
Interleukin-15
/ blood
Leukocyte Common Antigens
/ metabolism
Lymphocytes, Tumor-Infiltrating
/ immunology
Middle Aged
Neoplasm Staging
Neoplastic Cells, Circulating
/ pathology
Prognosis
Risk Factors
Stromal Cells
/ immunology
Transforming Growth Factor beta3
/ blood
Tumor Microenvironment
/ immunology
circulating tumor cells
cytokines
primary breast cancer
tumor-infiltrating lymphocytes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Dec 2020
12 Dec 2020
Historique:
received:
01
10
2020
revised:
07
12
2020
accepted:
10
12
2020
entrez:
16
12
2020
pubmed:
17
12
2020
medline:
20
3
2021
Statut:
epublish
Résumé
Circulating tumor cells (CTCs) and the immune infiltration of tumors are closely related to clinical outcomes. This study aimed to verify the influence of stromal lymphocyte infiltration and the immune context of tumor microenvironment on the hematogenous spread and prognosis of 282 chemotherapy naïve primary BC patients. To detect the presence of mesenchymal CTCs, RNA extracted from CD45-depleted peripheral blood was interrogated for the expression of mesenchymal gene transcripts. Tumor-infiltrating lymphocytes (TILs) were detected in the stromal areas by immunohistochemistry, using CD3, CD8, and CD45RO antibodies. The concentrations of 51 plasma cytokines were measured by multiplex bead arrays. TILs infiltration in mesenchymal CTC-positive patients significantly decreased their progression-free survival (HR = 4.88, 95% CI 2.30-10.37,
Identifiants
pubmed: 33322711
pii: ijms21249460
doi: 10.3390/ijms21249460
pmc: PMC7763628
pii:
doi:
Substances chimiques
CD3 Complex
0
CD8 Antigens
0
Chemokine CCL7
0
Cytokines
0
Interleukin-15
0
TGFB3 protein, human
0
Transforming Growth Factor beta3
0
Leukocyte Common Antigens
EC 3.1.3.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-16-0010
Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-16-0178
Organisme : ERA-NET EuroNanoMed II
ID : INNOCENT
Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : 1/0724/11
Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : 1/0044/15
Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : 1/0271/17
Organisme : Vedecká Grantová Agentúra MŠVVaŠ SR a SAV
ID : 2/0052/18
Références
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Histopathology. 2018 Dec;73(6):887-896
pubmed: 29947077
Ann Oncol. 2019 Oct 1;30(10):1541-1557
pubmed: 31373601
Breast Cancer Res. 2011 Jun 14;13(3):R61
pubmed: 21672237
NPJ Breast Cancer. 2020 May 12;6:17
pubmed: 32411819
J Clin Oncol. 2019 Mar 1;37(7):559-569
pubmed: 30650045
Nat Rev Immunol. 2020 Aug;20(8):483-497
pubmed: 32024984
Biomed Res Int. 2014;2014:415721
pubmed: 24895575
PLoS One. 2014 Apr 17;9(4):e95475
pubmed: 24743335
N Engl J Med. 2004 Aug 19;351(8):781-91
pubmed: 15317891
Eur J Cancer. 2008 Feb;44(3):472-80
pubmed: 18171612
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Cancer Immunol Immunother. 2020 Aug;69(8):1549-1564
pubmed: 32303794
Cancer Manag Res. 2019 Dec 27;11:10791-10800
pubmed: 31920388
J Cancer. 2016 Jun 03;7(9):1095-104
pubmed: 27326253
Cancer Res. 2019 Dec 15;79(24):6067-6073
pubmed: 31527091
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Clin Cancer Res. 2016 Dec 1;22(23):5747-5754
pubmed: 27189162
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Cancers (Basel). 2020 May 01;12(5):
pubmed: 32369910
Ann Oncol. 2014 Aug;25(8):1536-43
pubmed: 24915873
BMC Cancer. 2016 Feb 19;16:127
pubmed: 26896000
Mol Cancer Ther. 2019 Feb;18(2):437-447
pubmed: 30401696
Cancer Immunol Res. 2017 Sep;5(9):812-820
pubmed: 28811289
Int J Cancer. 2012 Feb 15;130(4):808-16
pubmed: 21387303
Cancer Cell. 2011 Nov 15;20(5):576-90
pubmed: 22094253
Anticancer Res. 2019 Apr;39(4):1829-1837
pubmed: 30952723
Oncol Lett. 2019 Mar;17(3):2647-2656
pubmed: 30867728
Carcinogenesis. 2012 May;33(5):949-55
pubmed: 22425643
BMC Med. 2015 Aug 24;13:202
pubmed: 26300242
Front Oncol. 2019 Feb 21;9:82
pubmed: 30847298
Signal Transduct Target Ther. 2020 Mar 12;5(1):28
pubmed: 32296047
Mediators Inflamm. 2014;2014:141747
pubmed: 24891760
PeerJ. 2018 Jun 14;6:e4928
pubmed: 29915688
Nat Rev Immunol. 2015 Dec;15(12):771-83
pubmed: 26567920
Anticancer Res. 2013 Feb;33(2):737-42
pubmed: 23393376
Br J Cancer. 2003 Apr 7;88(7):1091-4
pubmed: 12671691
Oncoimmunology. 2018 Nov 5;8(2):e1537691
pubmed: 30713794
Lancet Oncol. 2014 Apr;15(4):406-14
pubmed: 24636208
Histopathology. 2011 Jun;58(7):1107-16
pubmed: 21707712
Biomed J. 2020 Feb;43(1):18-23
pubmed: 32200952
Cell Rep. 2016 Mar 15;14(10):2281-8
pubmed: 26947068
Cancer Commun (Lond). 2019 Jan 3;39(1):1
pubmed: 30606259
Cancer Manag Res. 2017 Nov 23;9:691-700
pubmed: 29200889
Oncoimmunology. 2014 Feb 14;3:e27926
pubmed: 25340002
Tumour Biol. 2017 Apr;39(4):1010428317695023
pubmed: 28378631
Eur J Cancer. 1992;28A(4-5):859-64
pubmed: 1524909
Oncol Lett. 2018 Sep;16(3):3045-3053
pubmed: 30127895
Indian J Med Res. 2014 Sep;140(3):361-9
pubmed: 25366203